284 related articles for article (PubMed ID: 3087513)
1. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Ralston SH; Alzaid AA; Gardner MD; Boyle IT
Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
[TBL] [Abstract][Full Text] [Related]
2. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
Tan TT; Alzaid AA; Sutcliffe N; Gardner MD; Thomson JA; Boyle IT
Postgrad Med J; 1988 Mar; 64(749):224-7. PubMed ID: 3174541
[TBL] [Abstract][Full Text] [Related]
4. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
Cantwell BM; Harris AL
Br Med J (Clin Res Ed); 1987 Feb; 294(6570):467-9. PubMed ID: 3103730
[TBL] [Abstract][Full Text] [Related]
5. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
Sawyer N; Newstead C; Drummond A; Cunningham J
Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
[TBL] [Abstract][Full Text] [Related]
6. [Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism].
Christensen JH; Kristiansen JH
Ugeskr Laeger; 1992 Nov; 154(47):3341-2. PubMed ID: 1462441
[TBL] [Abstract][Full Text] [Related]
7. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
Sekine M; Takami H
Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
[TBL] [Abstract][Full Text] [Related]
8. Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy.
Ralston SH; Gardner MD; Jenkins AS; McKillop JH; Boyle IT
Bone Miner; 1987 May; 2(3):227-42. PubMed ID: 2974309
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT
Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894
[TBL] [Abstract][Full Text] [Related]
10. Therapy of malignancy-associated hypercalcemia: 1983.
Stewart AF
Am J Med; 1983 Mar; 74(3):475-80. PubMed ID: 6219580
[TBL] [Abstract][Full Text] [Related]
11. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.
Varache N; Audran M; Clochon P; Lortholary A; Bouachour G; Alquier P; Basle MF
Clin Rheumatol; 1991 Sep; 10(3):328-32. PubMed ID: 1790647
[TBL] [Abstract][Full Text] [Related]
12. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
Thiébaud D; Jacquet AF; Burckhardt P
Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy.
Hosking DJ; Gilson D
Q J Med; 1984; 53(211):359-68. PubMed ID: 6484118
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.
Selby PL; Davies M; Marks JS; Mawer EB
Clin Endocrinol (Oxf); 1995 Nov; 43(5):531-6. PubMed ID: 8548936
[TBL] [Abstract][Full Text] [Related]
15. Medical management of hypercalcaemia.
Ralston SH
Br J Clin Pharmacol; 1992 Jul; 34(1):11-20. PubMed ID: 1633063
[TBL] [Abstract][Full Text] [Related]
16. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
Zojer N; Keck AV; Pecherstorfer M
Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
[TBL] [Abstract][Full Text] [Related]
17. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
[TBL] [Abstract][Full Text] [Related]
18. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.
Boudailliez BR; Pautard BJ; Sebert JL; Kremp O; Piussan CX
Pediatr Nephrol; 1990 Sep; 4(5):510-1. PubMed ID: 2242318
[TBL] [Abstract][Full Text] [Related]
19. Current management of malignant hypercalcaemia.
Stevenson JC
Drugs; 1988 Aug; 36(2):229-38. PubMed ID: 3053127
[TBL] [Abstract][Full Text] [Related]
20. Treatment of malignant hypercalcaemia with clodronate.
Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
